title: VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
abstract: There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care in Europe but is not routinely available in the UK. Data were collected retrospectively on patients who received vinfluine as a second-line treatment. The aims were to document the toxicity and efficacy in a real life setting. Data were collected on 49 patients from 9 sites across the UK and Ireland [median age, 64 (IQR, 57-70) years, 33 males]. All patients had advanced metastatic TCCU. Thirteen patients had bone or liver metastases, 4 patients had PS 2 and 11 patients had HB <10. Median vinflunine administration was 3.5 cycles (range 1-18). Most common grade 3-4 toxicities were constipation (4 patients) and fatigue (3 patients). Partial response rate was 29% (14 PR, 11 SD, 19 PD, 4 NE, 1 not available). Median OS was 9.1 (6.0, 12.7) months. Results are consistent with real life data from Europe. Toxicity is further reduced with prophylactic laxative and oral antibiotics. Vinflunine is an efficient and tolerable second line treatment in advanced TCCU.
authors.affiliation: University of Liverpool, Liverpool L69 3GA, UK.
authors.forename: Syed A
authors.initials: SA
authors.lastname: Hussain
authors.affiliation: Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK.
authors.forename: Jawaher
authors.initials: J
authors.lastname: Ansari
authors.affiliation: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5NG, UK.
authors.forename: Robert
authors.initials: R
authors.lastname: Huddart
authors.affiliation: The Mercy University Hospital, Wilton, Cork T12 WE28, Republic of Ireland.
authors.forename: Derek G
authors.initials: DG
authors.lastname: Power
authors.affiliation: The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
authors.forename: Jeanette
authors.initials: J
authors.lastname: Lyons
authors.affiliation: The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
authors.forename: James
authors.initials: J
authors.lastname: Wylie
authors.affiliation: Royal Free Hospital, London NW3 2QG, UK.
authors.forename: Maria
authors.initials: M
authors.lastname: Vilarino-Varlela
authors.affiliation: University of Liverpool, Liverpool L69 3GA, UK.
authors.forename: Nils O
authors.initials: NO
authors.lastname: Elander
authors.affiliation: Northern Centre for Cancer Care, Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK.
authors.forename: Rhona
authors.initials: R
authors.lastname: McMenemin
authors.affiliation: St George's Healthcare Trust, Tooting, London SW17 0QT, UK.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Pickering
authors.affiliation: Northampton General Hospital Trust, Cliftonville, Northampton NN1 5BD, UK.
authors.forename: Guy
authors.initials: G
authors.lastname: Faust
authors.affiliation: University of Liverpool, Liverpool L69 3GA, UK.
authors.forename: Seema
authors.initials: S
authors.lastname: Chauhan
authors.affiliation: University of Liverpool, Liverpool L69 3GA, UK.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Jackson
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007494:Ireland; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D006113:United Kingdom; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019459:Urothelium / Q000473:pathology; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C111217:vinflunine; D014747:Vinblastine